Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Akero Therapeutics | 2024 | Post Ipo Equity | $366.9M | Cambridge |
| Applied Therapeutics | 2024 | Post Ipo Equity | $100.0M | New York |
| ProfoundBio | 2024 | Series B | $112.0M | Seattle |
| Attralus | 2024 | Series B | $56.0M | San Francisco |
| Tyra Biosciences | 2024 | Post Ipo Equity | $200.0M | Carlsbad |
| Entact Bio | 2024 | Series Unknown | $40.3M | Watertown |
| Verve Therapeutics | 2023 | Post Ipo Equity | $143.8M | Boston |
| Gracell Biotechnologies | 2023 | Post Ipo Equity | $100.0M | Suzhou |
| Caribou Biosciences | 2023 | Post Ipo Equity | $125.0M | Berkeley |
| TwinStrand Biosciences | 2023 | Series Unknown | $10.3M | Seattle |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 151 | Akero Therapeutics | Post Ipo Equity | $366.9M | Cambridge, United States |
| 152 | Applied Therapeutics | Post Ipo Equity | $100.0M | New York, United States |
| 153 | ProfoundBio | Series B | $112.0M | Seattle, United States |
| 154 | Attralus | Series B | $56.0M | San Francisco, United States |
| 155 | Tyra Biosciences | Post Ipo Equity | $200.0M | Carlsbad, United States |
| 156 | Entact Bio | Series Unknown | $40.3M | Watertown, United States |
| 157 | Verve Therapeutics | Post Ipo Equity | $143.8M | Boston, United States |
| 158 | Gracell Biotechnologies | Post Ipo Equity | $100.0M | Suzhou, China |
| 159 | Caribou Biosciences | Post Ipo Equity | $125.0M | Berkeley, United States |
| 160 | TwinStrand Biosciences | Series Unknown | $10.3M | Seattle, United States |
Akero Therapeutics is a biotechnology company focused on reversing the NASH epidemic by restoring the body’s metabolism to a balanced state.
Applied Therapeutics uses drug-development approach to target molecules and pathways that has roles in fatal or debilitating diseases.
ProfoundBio is a developer of targeted therapeutics intended for patients with cancer.
Attralus is a biopharmaceutical company focusing on creating transformative medicines to improve the lives of patients.
Tyra Biosciences is a biotechnology company targeting new pathways of acquired resistance in oncology with purpose-built drugs.
Entact Bio is a biotechnology company that is in the preclinical stages of developing medications to improve protein function.
Verve Therapeutics is a clinical-stage biotechnology company developing genetic medicines for cardiovascular disease.
Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer.
Caribou Biosciences is a biotechnology company that develops CRISPR technologies and allogenic cell therapies for oncology.
TwinStrand Biosciences develops and commercializes the duplex sequencing technology for DNA sequencing.
IGM Biosciences is a biotechnology company that develops medicine for people with infectious infections, autoimmune diseases, and cancer.
Elevation Oncology is a clinical-stage biopharmaceutical company focused on the development of precision medicines for patients.
Synthekine is a development stage biotherapeutics company focused on the engineering of novel specific and potent cytokine therapies.
Loadsmart is a next-gen freight technology platform and 4PL that lower costs, increase efficiency, and digitize transportation for Shippers.
Chinook Therapeutics is a biotechnology company that specializes in the fields of therapeutics and life science.
IntelyCare is revolutionizing healthcare staffing, scheduling, and training by offering an enterprise workforce management platform.
Magenta Therapeutics is a new biotechnology company developing therapeutics that unlock the power of stem cell biology.
Graphite Bio is a next-generation gene editing company that is driven to apply our breakthrough technology.
DTx Pharma is a biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease.
Artiva Biotherapeutics is a biotech company focused on developing and commercializing allogeneic natural killer (NK) cell therapies.
Cyteir is developing the next generation of synthetic lethal therapies to treat cancer.
Decibel Therapeutics is a hearing company focused on discovering and developing new medicines to protect, repair, and restore hearing.
Flame Biosciences is a clinical-stage company focused on therapies for cancer and other inflammatory diseases.
Rain Oncology is a operator of a clinical stage biotechnology company.
Sojournix is a biotechnology company developing innovative medicines for women's health and endocrine disorders.
Janus Henderson Investors has invested in 175 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Janus Henderson Investors's top investment sectors include Biotechnology, Therapeutics, Health Care, Medical, Life Science. The firm invests across 18 different industry categories.
Among tracked funding rounds, Akero Therapeutics received $366.9M in a Post Ipo Equity round. Janus Henderson Investors's total known invested capital is $12.5B.
Janus Henderson Investors's average investment size is $129.0M across its portfolio of 175 companies.
Recent Janus Henderson Investors portfolio additions include Akero Therapeutics, Applied Therapeutics, ProfoundBio, Attralus, Tyra Biosciences. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors